ATAI LIFE SCIENCES NV (ATAI) Stock News
NASDAQ:ATAI - Nasdaq - NL0015000DX5 - Common Stock - Currency: USD
ATAI Latest News, Press Relases and Analysis
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Mentions: CAH
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies
Jefferies analyst Andrew Tsai notes that Beckley Psytech shared positive Phase 2a data on BPL-003 in combination with SSRI antidepressants for treatment-resistant depression that the firm calls “encouraging.” The drug’s profile seems to be consistent across multiple studies, incrementally de-risking the key Phase 2b TRD study in mid-2025, the analyst tells investors. Although the BPL-003 program is controlled by Beckley Psytech, Atai Life Sciences (ATAI) currently holds about a 34% stake in Beck
Mentions: HD
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. aTyr Pharma, Inc. (NASDAQ:ATYR) was one of the stocks that was covered in that article. Wall Street analysts believe ATYR has a 485% upside potential over the next 12 months. aTyr Pharma, Inc. (NASDAQ:ATYR) stands as a pioneering biotherapeutics company dedicated to […]
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to...
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments ...
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to...
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Atai Life Sciences (NASDAQ:ATAI) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published […]
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data...
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
- The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
atai Life Sciences Announces Pricing of Public Offering of Common Shares
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical...
atai Life Sciences Announces Proposed Public Offering of Common Shares
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients...
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to...
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.